Magnetocardiography in the Accurate Identification of Myocardial Infarction

Last updated: September 27, 2025
Sponsor: Qilu Hospital of Shandong University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pain

Blood Clots

Coronary Artery Disease

Treatment

Magnetometer

Clinical Study ID

NCT05896826
QLEmer-MCG
  • Ages 18-79
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Magnetocardiography (MCG) is a promising noninvasive and accurate method for detecting myocardial infarction. Although progress has been made in this area, there is a lack of studies using up-to-date examination instruments for the calibration of MCG analysis. This is a prospective single-center study aiming to build accurate analytical models of MCG to detect myocardial infarction. Myocardial infarction are diagnosed by electrocardiogram, biomarkers (high-sensitivity cardiac troponin, etc), or non-invasive imaging (cardiac magnetic resonance or single-photon-emission tomography). Myocardial infarction is also quantified by cardiac magnetic resonance or single-photon-emission tomography. Healthy volunteers and chest pain patients who will receive electrocardiogram, biomarkers (high-sensitivity cardiac troponin, etc), or non-invasive imaging (cardiac magnetic resonance or single-photon-emission tomography) examination will be enrolled in this study.

Eligibility Criteria

Inclusion

For healthy volunteers:

Inclusion Criteria:

  1. Age 18-79 years old;

  2. No history of cardiovascular disease (coronary heart disease, structural heartdisease, arrhythmia, heart failure, stroke, pulmonary embolism, aortic dissection,etc.), no cardiovascular risk factors (hypertension, diabetes, hyperlipidemia). Forpeople over 65 years old, those with hypertension or hyperlipidemia, but withwell-controlled blood pressure and lipid levels, taking no more than 2 drugs, andechocardiography showing no left ventricular hypertrophy, can be included;

  3. The electrocardiogram is normal, and the cardiac ultrasound is basically normal inthe past 1 year (mild valvular regurgitation can be included).

  4. Sign the informed consent.

Exclusion

Exclusion Criteria:

  1. Those who with acute or chronic respiratory diseases;

  2. Those who with obvious abnormality of liver or kidney function;

  3. Those who with endocrine diseases such as abnormal thyroid function;

  4. Those who with anemia or other blood diseases;

  5. Those who with connective tissue diseases (lupus erythematosus, rheumatoidarthritis, dermatomyositis, polyarteritis nodosa, etc.);

  6. Those who are obese (BMI>30kg/cm2) or underweight (BMI<18kg/cm2);

  7. Those who with malignant tumors;

  8. Those who with infectious diseases or infectious diseases;

  9. Those who with trauma or physical disability;

  10. Those who with psychological or mental illness such as depression;

  11. Those who are professional athletes, pregnant or breastfeeding women, alcoholics;

  12. Those who are unable to perform magnetocardiography examination due toclaustrophobia, etc., or those who fail to receive magnetocardiography examination;

  13. Due to various reasons such as allergy to contrast agents, metal implants in vivothat are prohibited from performing 1.5T MRI (such as prostheses or steel platesimplanted in orthopaedics, uterine contraceptive device) and other reasons, thosewho cannot or fail to cooperate with the corresponding research requirements.

For chest pain patients who will receive ECG, biomarkers, or non-invasive imaging examination:

Inclusion Criteria:

  1. Age 18-79 years old;

  2. Those with chest pain symptoms, diagnosed or highly suspected by the attendingdoctor or above as stable angina pectoris (SA), unstable angina pectoris (UA),non-ST segment elevation myocardial infarction (NSTEMI), ST segment elevationmyocardial infarction (STEMI), and plan to receive electrocardiogram, biomarkers (high-sensitivity cardiac troponin, etc), or non-invasive imaging (cardiac magneticresonance or single-photon-emission tomography);

  3. Sign the informed consent.

Exclusion Criteria:

  1. Patients with known structural heart disease such as cardiomyopathy and valvulardisease;

  2. Patients with arrhythmias such as atrial fibrillation, supraventricular tachycardia,and atrioventricular block that have not returned to normal;

  3. History of other cardiovascular diseases such as pulmonary embolism and aorticdissection;

  4. Patients with connective tissue diseases (lupus erythematosus, rheumatoid arthritis,dermatomyositis, polyarteritis nodosa, etc.) combined with cardiac complications;

  5. Obvious abnormal thyroid function, severe anemia or other blood diseases and otherdiseases that obviously affect the circulating blood supply;

  6. Obese (BMI>30kg/cm2) or underweight (BMI<18kg/cm2);

  7. Patients with malignant tumors;

  8. Professional athletes, pregnant or breastfeeding women, alcoholics;

  9. Acute diseases or critical illnesses in other systems, such as acute or severerespiratory diseases, abnormal liver function or renal function, etc.;

  10. Patients with infectious diseases or infectious diseases;

  11. Those who are unable or fail to perform magnetocardiography due to claustrophobia,physical impairment, etc.;

  12. Unable to or fail to cooperate with the corresponding research requirements.

Study Design

Total Participants: 3841
Treatment Group(s): 1
Primary Treatment: Magnetometer
Phase:
Study Start date:
June 01, 2023
Estimated Completion Date:
December 01, 2026

Connect with a study center

  • Qilu Hospital of Shandong University

    Jinan, Shandong 250012
    China

    Site Not Available

  • Qilu Hospital of Shandong University

    Jinan 1805753, Shandong 1796328 250012
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.